Trust Point’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$144K Buy
+31,048
New +$138K 0.01% 506
2026
Q2
– Sell
-31,048
Closed -$129K – 489
2026
Q1
$129K Buy
31,048
+7,000
+29% +$28.4K 0.01% 514
2025
Q4
$155K Buy
24,048
+1,595
+7% +$9.9K 0.01% 475
2025
Q3
$126K Buy
+22,453
New +$97.1K 0.01% 476
2025
Q2
– Sell
-23,396
Closed -$67.8K – 409
2025
Q1
$67.8K Buy
23,396
+9,625
+70% +$29.1K 0.01% 456
2024
Q4
$49K Hold
13,771
– – ﹤0.01% 559
2024
Q3
$68.6K Hold
13,771
– – 0.01% 513
2024
Q2
$35.8K Hold
13,771
– – ﹤0.01% 494
2024
Q1
$58.7K Buy
13,771
+3,726
+37% +$12.4K ﹤0.01% 523
2023
Q4
$20.3K Buy
+10,045
New +$17.8K ﹤0.01% 495

Other funds holding AQST

Trust Point's AQST Position: Q3 2026 in Review

Trust Point opened a new position in Aquestive Therapeutics (AQST) in Q3 2026: 31,048 shares worth $144K. The stake represents 0.01% of the portfolio and ranks #506 among its holdings. This is a return to the name: Trust Point previously reported a position in AQST as recently as Q1 2026.

Trust Point first reported a position in AQST in Q4 2023 and has held it in 10 quarters since. The position peaked at $155K in Q4 2025. 142 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Trust Point held 31,048 shares of Aquestive Therapeutics worth $144K as of Q3 2026.
  • Aquestive Therapeutics was a new Trust Point position in Q3 2026.
  • Aquestive Therapeutics made up 0.01% of Trust Point's portfolio in Q3 2026, its #506 holding.
  • Trust Point first reported a position in Aquestive Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Trust Point's Aquestive Therapeutics position peaked at $155K in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.